Most Recent
Law firm Norton Rose Fulbright has rejected findings of dishonesty, deceit and abuse of process in seeking to overturn a $160,000 judgment against it, saying it had no "evil intent" in litigating a long-running dispute with former partner Thomas Martin.
A judge has expanded a freezing order over assets owned by Forum Finance director Vincenzo Tesoriero to include property outside Australia, including a yacht in Miami dubbed “XOXO”, after Westpac raised concerns about non-disclosure.
Cricket Australia must hand over documents to Seven West Media as the TV network weighs potential legal action for damages against the league over the quality of the 2020-2021 summer cricket season.
7-Eleven has told a court it is willing to negotiate a deal with Seven over the 7NOW logo, a trade mark the TV network recently lost after a successful challenge by the convenience store chain.
A former Norton Rose Fulbright partner locked in a six-year legal battle with the firm has urged the Full Court to allow a $160,000 damages award in his favour to be recalculated, saying it did not provide enough "sting", amounting to just $1,500 per partner.
The Commonwealth Bank of Australia has slammed an attempt by a class action to “trawl through” its Chief Executive Officer’s emails in search of correspondence regarding it decision to rebate commissions grandfathered by the Future of Financial Advice reforms.
National Australia Bank has been hit with a $18.5 million fine after admitting to allegations by ASIC that it failed to adequately disclose its adviser fees for five years.
A judge overseeing a Papua New Guinean politician’s defamation lawsuit has criticised Nine’s refusal to take down two allegedly defamatory articles ahead of a delayed trial, saying there was no reason to keep them online except for the publisher’s “pride or ego”.
In a recent decision, the Full Federal Court confirmed that a trade mark owner who merely authorises use of its trade mark cannot be subject to liability for direct trade mark infringement under section 120(1) of the Trade Marks Act, writes Shelston IP's Kathy Mytton and Sean McManis.
Swiss pharmaceutical company Biogen is seeking a court order blocking an Australian generic drug manufacturer from selling a cheap multiple sclerosis drug it claims infringes its patent for medicine Tecfidera, a court has heard.